KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Receivables - Net: 2017-2024

Historic Receivables - Net for BeOne Medicines (ONC) over the last 8 years, with Dec 2024 value amounting to $676.3 million.

  • BeOne Medicines' Receivables - Net rose 51.71% to $863.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $863.3 million, marking a year-over-year increase of 51.71%. This contributed to the annual value of $676.3 million for FY2024, which is 88.89% up from last year.
  • BeOne Medicines' Receivables - Net amounted to $676.3 million in FY2024, which was up 88.89% from $358.0 million recorded in FY2023.
  • In the past 5 years, BeOne Medicines' Receivables - Net registered a high of $676.3 million during FY2024, and its lowest value of $60.4 million during FY2020.
  • Over the past 3 years, BeOne Medicines' median Receivables - Net value was $358.0 million (recorded in 2023), while the average stood at $402.5 million.
  • In the last 5 years, BeOne Medicines' Receivables - Net surged by 699.82% in 2021 and then crashed by 64.16% in 2022.
  • Over the past 5 years, BeOne Medicines' Receivables - Net (Yearly) stood at $60.4 million in 2020, then spiked by 699.82% to $483.1 million in 2021, then crashed by 64.16% to $173.2 million in 2022, then soared by 106.75% to $358.0 million in 2023, then skyrocketed by 88.89% to $676.3 million in 2024.